Medicenna Therapeutics Corp
TSX:MDNA

Watchlist Manager
Medicenna Therapeutics Corp Logo
Medicenna Therapeutics Corp
TSX:MDNA
Watchlist
Price: 1.01 CAD -0.98% Market Closed
Market Cap: 79m CAD

Net Margin
Medicenna Therapeutics Corp

0%
Current
0%
Average
-6.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-13.8m
/
Revenue
0

Net Margin Across Competitors

No Stocks Found

Medicenna Therapeutics Corp
Glance View

Market Cap
84.2m CAD
Industry
Biotechnology

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The company went IPO on 2015-07-13. The firm is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform is designed to enable the ability of Superkines to treat immunologically cold tumors. The Company’s product candidate MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. The firm has not earned any revenues from its products.

MDNA Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-13.8m
/
Revenue
0
What is the Net Margin of Medicenna Therapeutics Corp?

Based on Medicenna Therapeutics Corp's most recent financial statements, the company has Net Margin of 0%.

Back to Top